


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/907928/publications.pdf Version: 2024-02-01



FISA SOLÃE

#	Article	IF	CITATIONS
1	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. Journal of Hepatology, 2022, 76, 107-114.	1.8	21
2	Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut, 2022, 71, 148-155.	6.1	98
3	Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS ONE, 2022, 17, e0265153.	1.1	18
4	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatology Communications, 2022, 6, 1100-1112.	2.0	5
5	Assessment of kidney function in cirrhosis: Are we moving closer to accurate estimation of glomerular filtration rate?. Liver International, 2022, 42, 957-959.	1.9	0
6	Patterns of kidney dysfunction in acuteâ€onâ€chronic liver failure: Relationship with kidney and patients' outcome. Hepatology Communications, 2022, 6, 2121-2131.	2.0	8
7	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€onâ€chronic liver failure and acute decompensation. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 240-248.	1.4	11
8	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology, 2021, 160, 206-218.e13.	0.6	89
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
10	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. Journal of Hepatology, 2021, 74, 200-219.	1.8	16
11	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clinics in Liver Disease, 2021, 25, 441-460.	1.0	2
12	Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data― Gut, 2021, , gutjnl-2021-324926.	6.1	0
13	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). Digestive and Liver Disease, 2021, 53, 738-745.	0.4	5
14	The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673.	3.6	67
15	Liver cirrhosis. Lancet, The, 2021, 398, 1359-1376.	6.3	515
16	Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver International, 2021, 41, 2729-2732.	1.9	6
17	O09â€A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5
18	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	3.7	75

#	Article	IF	CITATIONS
19	Lack of evidence for a continuum between hepatorenal syndromeÂand acute tubular necrosis. Journal of Hepatology, 2020, 72, 581-582.	1.8	5
20	Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. Clinical Gastroenterology and Hepatology, 2020, 18, 1040-1042.	2.4	1
21	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	1.8	223
22	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
23	Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. Clinical and Translational Gastroenterology, 2020, 11, e00159.	1.3	32
24	Reply to: "Transition of AKI to CKD in cirrhosis – effect of baseline eGFR and unanswered questions― Journal of Hepatology, 2020, 73, 738-739.	1.8	0
25	Clinical Application of Kidney Biomarkers in Cirrhosis. American Journal of Kidney Diseases, 2020, 76, 710-719.	2.1	55
26	Chronic Kidney Disease in Cirrhosis: Emerging Complication With Negative Impact in the Liver Transplant Setting. Liver Transplantation, 2020, 26, 483-484.	1.3	2
27	Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. Journal of Hepatology, 2020, 72, 1132-1139.	1.8	43
28	Editorial: evaluating cirrhosis progressionâ€lessons from the heart. Alimentary Pharmacology and Therapeutics, 2019, 50, 709-710.	1.9	1
29	Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out…― Journal of Hepatology, 2019, 70, 812.	1.8	0
30	Distinct phenotype of CD4+ T cells driving celiac disease identified in multiple autoimmune conditions. Nature Medicine, 2019, 25, 734-737.	15.2	112
31	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	2.2	134
32	Neutrophil Gelatinaseâ€Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	3.6	114
33	Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter. Journal of Hepatology, 2019, 70, 828-830.	1.8	14
34	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	1.8	101
35	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International, 2019, 39, 1246-1255.	1.9	64
36	New Strategies for the Management of Decompensated Cirrosis: Longâ€Term Albumin Administration for Everyone?. Hepatology, 2019, 69, 2289-2291.	3.6	2

#	Article	IF	CITATIONS
37	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). GuÃa de práctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
38	Editorial: macrophage activation markers predict prognosis and decompensation in patients with cirrhosis—linking gut permeability, inflammation and cirrhosis progression. Alimentary Pharmacology and Therapeutics, 2018, 47, 851-853.	1.9	0
39	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in PatientsÂWith Hepatorenal Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 1792-1800.e3.	2.4	127
40	Actualización en la insuficiencia hepática aguda sobre crónica. GastroenterologÃa Y HepatologÃa, 2018, 41, 43-53.	0.2	11
41	Cell death markers in patients with cirrhosis and acute decompensation. Hepatology, 2018, 67, 989-1002.	3.6	76
42	Hepatorenal syndrome. Nature Reviews Disease Primers, 2018, 4, 23.	18.1	172
43	Hepatorenal syndrome in the era of acute kidney injury. Liver International, 2018, 38, 1891-1901.	1.9	42
44	Characterization of systemic inflammatory response in hepatorenal syndrome in cirrhosis. A major role for il-6, TNF-alpha, and VCAM. Journal of Hepatology, 2018, 68, S698.	1.8	3
45	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. Journal of Hepatology, 2018, 69, 1250-1259.	1.8	152
46	Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia. Journal of Clinical Lipidology, 2017, 11, 551-561.e7.	0.6	21
47	Acute-on-chronic liver failure: an update. Gut, 2017, 66, 541-553.	6.1	472
48	Effects of alfapumpâ,,¢ system on kidney and circulatory function in patients with cirrhosis and refractory ascites. Liver Transplantation, 2017, 23, 583-593.	1.3	37
49	Reply to: "Are we still searching for the fifth element of MELD?â€, Journal of Hepatology, 2017, 66, 247-248.	1.8	0
50	Pro: Acuteâ€onâ€chronic liver failure. Liver Transplantation, 2017, 23, 1318-1324.	1.3	3
51	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. Scientific Reports, 2017, 7, 1829.	1.6	30
52	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2017, 15, 438-445.e5.	2.4	125
53	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. American Journal of Medicine, 2017, 130, 372-375.	0.6	31
54	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Critical Care, 2017, 21, 321.	2.5	19

#	Article	IF	CITATIONS
55	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS ONE, 2016, 11, e0157371.	1.1	20
56	Acute-on-Chronic Liver Failure: The Role of Precipitating Illness. Seminars in Liver Disease, 2016, 36, 117-122.	1.8	22
57	Management of uninfected and infected ascites in cirrhosis. Liver International, 2016, 36, 109-115.	1.9	43
58	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	1.8	35
59	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Scientific Reports, 2016, 6, 32341.	1.6	101
60	The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic?. Current Hepatology Reports, 2016, 15, 53-59.	0.4	0
61	Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). Journal of Hepatology, 2016, 64, 813-822.	1.8	104
62	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 57-65.	1.8	112
63	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transplantation, 2015, 21, 1347-1354.	1.3	48
64	Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. Liver International, 2015, 35, 2079-2081.	1.9	4
65	Clinical Course of acuteâ€onâ€chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	3.6	493
66	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	1.1	97
67	Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI – To be or not to be― Journal of Hepatology, 2015, 62, 743-744.	1.8	2
68	Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis. Digestive Diseases, 2015, 33, 534-538.	0.8	20
69	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. Journal of Hepatology, 2015, 63, 593-600.	1.8	53
70	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut, 2015, 64, 1616-1622.	6.1	86
71	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. Critical Care, 2014, 18, 700.	2.5	41
72	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. Journal of Hepatology, 2014, 60, 955-961.	1.8	100

#	Article	IF	CITATIONS
73	From Refractory Ascites to Dilutional Hyponatremia and Hepatorenal Syndrome: Current Options for Treatment. Current Hepatology Reports, 2014, 13, 189-197.	0.4	1
74	Reply to: "To close the stable door before the horse has bolted― Journal of Hepatology, 2014, 60, 679-680.	1.8	0
75	Chronic kidney disease: A major concern in liver transplantation in the XXI century. Journal of Hepatology, 2014, 61, 196-197.	1.8	7
76	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. Journal of Hepatology, 2014, 61, 35-42.	1.8	98
77	A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. Journal of Hepatology, 2013, 59, 474-481.	1.8	249
78	Current treatment strategies for hepatorenal syndrome. Clinical Liver Disease, 2013, 2, 136-139.	1.0	2
79	Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Current Opinion in Organ Transplantation, 2013, 18, 265-270.	0.8	10
80	Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology, 2012, 56, 1040-1046.	1.8	50
81	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Journal of Hepatology, 2012, 57, 267-273.	1.8	191
82	Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology, 2012, 57, 1199-1206.	1.8	116
83	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology, 2011, 140, 488-496.e4.	0.6	311
84	Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology, 2010, 51, 219-226.	3.6	211
85	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology, 2010, 52, 1783-1790.	3.6	88
86	Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. Journal of Hepatology, 2010, 53, 1135-1145.	1.8	97